Breaking News

BioNJ Creates Clinical Trials Master Service Agreement Template

By Kristin Brooks | February 26, 2014

Aims to streamline clinical trials

BioNJ has established a Clinical Trials Master Service Agreement template designed to support clinical trial facilitation in Phases II through IV. The form is available at no cost by contacting BioNJ@BioNJ.org.
 
The project was a collaboration between BioNJ, Rutgers University, and the law firm of Sheppard Mullin Richter & Hampton LLP, and has been reviewed and endorsed by Rutgers and Rowan University.
 
“The purpose of the form is to reduce the negotiation time for translation studies being conducted at New Jersey institutions,” said BioNJ president and chief executive officer Debbie Hart. “Our objective is to free up much needed resources and time for research, accelerating the development of state-of-the-art therapeutics and diagnostics emerging from research discoveries.”
 
Although some studies may require modification to the form for specific trial needs, the template aims to provide a reliable starting point for sponsors collaborating with NJ research institutions. Guidance documents will be developed over the next few months to help users better understand key issues addressed in the form. Future plans of the working group will include forms for Letters of Indemnification, Guidance on Subject Injury and Sponsor Insurance Coverages.
 
 

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research